Navigation Links
Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
Date:10/6/2008

the risk that clinical trials for Genaera's product candidates including trodusquemine (MSI-1436) and the IL-9 antibody program may be delayed or may not be successful; the risk that Genaera may not obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and interpreting data, regulatory interpretations of clinical risk and benefit, or otherwise; Genaera's reliance on its collaborator, in connection with the development and commercialization of Genaera's IL-9 antibody program; market acceptance of Genaera's products, if regulatory approval is achieved; competition; general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industry; and the other risks and uncertainties discussed in this announcement and in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at http://www.sec.gov as well as other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Genaera does not intend (and it is not obligated) to publicly update, revise or correct these forward-looking statements or the risk factors that may relate thereto.


'/>"/>
SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
2. Genaera Corporation Presents Data on Mechanism of Inhibition of PTP-1B for Trodusquemine (MSI-1436) at Federation of American Societies for Experimental Biology (FASEB) Meeting
3. Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
4. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
5. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
6. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
7. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
8. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
9. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
10. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
11. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 STAAR Surgical Company (NASDAQ: ... marketer of implantable lenses and delivery systems for the ... results and conference call with investors to July 31, ... The Company rescheduled the release date and conference call ... for Hideo Watanabe , President of STAAR Japan, ...
(Date:7/28/2014)... SOUTH SAN FRANCISCO, Calif. , July 28, 2014 ... ) today provided an update on the status of ... KB001-A collaboration with Sanofi Pasteur.  ... has reached an agreement with Sanofi Pasteur to regain ... the collaboration and licensing agreement entered into in 2010 ...
(Date:7/28/2014)... July 28, 2014  Serco Inc., a provider ... Company has been awarded a re-compete contract to ... and its Deployable Medical Systems.  Serco will provide ... to provide world-class healthcare to meet warfighter and ... the globe. The five year contract has a ...
Breaking Medicine Technology:STAAR Surgical Moves Second Quarter Earnings Release and Conference Call One Day to July 31 2KaloBios Provides Update on KB001-A Partnership and Clinical Status 2KaloBios Provides Update on KB001-A Partnership and Clinical Status 3KaloBios Provides Update on KB001-A Partnership and Clinical Status 4KaloBios Provides Update on KB001-A Partnership and Clinical Status 5KaloBios Provides Update on KB001-A Partnership and Clinical Status 6Serco Awarded $22.7 Million Contract to Support Deployable Medical Systems 2
... Iceland, December 14 In one of the,largest studies ... from,deCODE genetics (Nasdaq: DCGN ) today report the ... human genome found to influence obesity. The study,analyzed more ... than 30,000 people from Iceland, the Netherlands, and the ...
... data from two early,clinical studies show that RAD001(R) (everolimus) ... metastatic breast,cancer. These results support the initiation of a ... of RAD001 (proposed brand name,Afinitor(R)) in breast cancer. , ... studies were presented today during the CTRC-AACR San Antonio,Breast ...
Cached Medicine Technology:Major deCODE-led Study Underscores Role of the Brain in Obesity 2Major deCODE-led Study Underscores Role of the Brain in Obesity 3Major deCODE-led Study Underscores Role of the Brain in Obesity 4Major deCODE-led Study Underscores Role of the Brain in Obesity 5RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial 2RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial 3RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial 4RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial 5RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial 6RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial 7
(Date:7/28/2014)... controlling red blood cell development have spread from Africa ... to a new study led by King,s College London. ... to look for the origin of changes in a ... adulthood. Fetal haemoglobin is normally found in fetuses and ... are able to keep making it as adults experience ...
(Date:7/28/2014)... NAPW honors Pamela ... Center, as a 2014 Professional Woman of the Year. ... leadership in community health. As the largest, most-recognized networking ... industry and profession, the National Association of Professional Women ... 600,000 members and nearly 300 Local Chapters. , In ...
(Date:7/28/2014)... 2014 Evolve Medical Clinics opened its first ... members virtual visits and dramatic operational changes that are set ... state that as many as 70% of all primary and ... to leave your office or home for a throat infection, ... cholesterol,” CEO and Founder Michael R. Freedman, MD said. “Doctor’s ...
(Date:7/28/2014)... The “Tissue Diagnostics Market by ... & Workflow, Special Staining), Disease (Breast Cancer, ... Cell Lung Cancer and Others), Product (Instruments ... Laboratories, Contract Research Organizations and Others) & ... & RoW) - Trends & Forecast to ...
(Date:7/28/2014)... Dallas, Texas (PRWEB) July 29, 2014 ... provides key market data on the China Surgical ... of US dollars, volume (in units) and average ... RF Generators, Electrocautery Generators, Ultrasonic Generators and Argon ... company shares and distribution shares data for each ...
Breaking Medicine News(10 mins):Health News:Study tracks worldwide spread of beneficial blood cell gene variant 2Health News:Study tracks worldwide spread of beneficial blood cell gene variant 3Health News:National Association of Professional Women Announces Pamela A. Schulters, Head Nurse at Kings County Hospital Center, a 2014 Professional Woman of the Year 2Health News:Evolve Medical Clinics to Open First Next Generation Primary and Urgent Care Facility 2Health News:Evolve Medical Clinics to Open First Next Generation Primary and Urgent Care Facility 3Health News:Evolve Medical Clinics to Open First Next Generation Primary and Urgent Care Facility 4Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 2Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 3Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 4Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 5Health News:Key Market Data on China Surgical Generators Market to 2020 Report Available at MarketOptimizer.org 2Health News:Key Market Data on China Surgical Generators Market to 2020 Report Available at MarketOptimizer.org 3Health News:Key Market Data on China Surgical Generators Market to 2020 Report Available at MarketOptimizer.org 4
... rhinosinusitis – an often recurring combination of congestion, discolored ... quality of life. ,A group of 25 physicians ... the first clinical trial guidelines for researchers working to ... ,The U.S. Food and Drug Administration (FDA) has issued ...
... be overcome by a newly developed vaccine according to ... funds from the government, said that their vaccine worked ... mice. This bacteria causes a range of potentially fatal ... ,Most hospital-acquired infections are commonly caused by it, causing ...
... convey the poisonous toxic meth chemicals to their unborn fetus ... Study. , ,Motherisk lab at the Hospital for Sick ... of adults and young children to gauge their exposure to ... from the expectant mother to the unborn child. ...
... Stern Review as a timely and authoritative reminder of ... world’s human population if the international community failed to ... prepared by former World Bank chief economist, Sir Nicholas ... Minister, Tony Blair, as the most important he has ...
... commonly prescribed invasive test performed during pregnancies in the ... them based on guidelines from the American College of ... studies and recommendations by the CDC that were based ... have suggested that amniocentesis increases the rate of miscarriage ...
... a recent research, an infant’s risk of cot death or ... defects that affect breathing and temperature control. // ... SIDS. The findings were published in the Journal of the ... these infants had flaws in their brainstem that affected the ...
Cached Medicine News:Health News:New Rhinosinusitis Clinical Trials Guidance Developed 2Health News:Vaccine may overcome Common Infections: Researchers 2Health News:A Timely Reminder Of Devastating Health Impact Of Climate Change 2Health News:Amniocentesis Safer for Pregnant Women 2Health News:Brain stem Defects associated with SIDS 2
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTC/1Q chairs are recommended for ... clean room, static control, health care ...
... concave seats and standard-sized backrests with ... seats, backrests, armrests, and casters and ... for the following environments: industry, education, ... care and office. • With cast ...
... concave seats and standard-sized backrests with ... seats, backrests, armrests, and casters and ... for the following environments: industry, education, ... care and office. • With cast ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... chairs are recommended for the following ... static control, health care and office. ...
Medicine Products: